Brain Metastases in Epithelial Ovarian Carcinoma

Geisler, John P.; Geisler, Hans

doi:10.1006/gyno.1995.1134

Cited by 90 publications

(94 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Brain metastases from EOC are rare and a late manifestation of the disease that occurs in patients with prolonged survival as a result of platinum-based chemotherapy. The incidence of brain metastases from EOC ranges from 0.29% to 5% [6][7][8]. Some reports have indicated that the rate is >5% and approaching 12% [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

2006

View full text Add to dashboard Cite

Key Words. Brain metastases • Surgery • Stereotactic radiosurgery • Whole-brain radiotherapy • Chemotherapy Learning ObjectivesAfter completing this course, the reader will be able to:1. Select the appropriate treatment strategies for ovarian cancer patients with solitary brain metastases and extracranial disease.2. Describe the most important prognostic factors for ovarian cancer patients with brain metastases.3. List the diagnostic steps needed to establish the diagnosis of brain metastases in ovarian cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

2006

View full text Add to dashboard Cite

show abstract

“…First, despite the tendency to present at advanced International Federation of Gynecology and Obstetrics (FIGO ) stage reflected by the observation that nearly 73% of ovarian cancers are no longer confined to the ovary at diagnosis, 2 this cancer often remains confined within the abdominal cavity throughout its course. 3,4 Second, initial, complete clinical responses are the expected norm following surgical cytoreduction and adjuvant systemic chemotherapy. Unfortunately, recurrence, progression, and death from disease is the eventual outcome for more than 75% of women diagnosed with epithelial ovarian cancer.…”

mentioning

confidence: 99%

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

et al. 2002

View full text Add to dashboard Cite

Purpose: To determine the safety, gene transfer, host immune response, and pharmacokinetics of a replication -deficient adenovirus encoding human, recombinant, wild -type p53 ( SCH 58500 ) delivered into the peritoneal cavity ( i.p. ) alone and sequentially in combination with platinum -based chemotherapy, of patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer containing aberrant or mutant p53. Methods: SCH 58500 was administered i.p. to three groups of patients with heavily pretreated recurrent disease. Group 1 ( n = 17 ) received a single dose of SCH 58500 escalated from 7.5Â10 10 to 7.5Â10 12 particles. Group 2 ( n = 9 ) received two or three doses of SCH 58500 given alone for one cycle, and then with chemotherapy for two cycles. The SCH 58500 dose was further escalated to 2.5Â10 13 particles / dose in group 2. A third group ( n = 15 ) received a 5 -day regimen of SCH 58500 given at 7.5Â10 13 particles / dose per day i.p. alone for cycle 1 and then with intravenous carboplatin / paclitaxel chemotherapy for cycles 2 and 3. Results: No dose -limiting toxicity resulted from the delivery of 236 / 287 ( 82.2% ) planned doses of SCH 58500. Fever, hypotension abdominal complaints, nausea, and vomiting were the most common adverse events. Vectorspecific transgene expression in tumor was documented by RT -PCR in cells from both ascitic fluid and tissue biopsies. Despite marked increases in serum adenoviral antibody titers, transgene expression was measurable in 17 of 20 samples obtained after two or three cycles of SCH 58500. Vector was detectable in peritoneal fluid by 24 hours and persisted for as long as 7 days whereas none was detected in urine or stool. There was poor correlation between CT scans and CA125 responses. CA125 responses, defined as a greater than 50% decrement in serum CA125 from baseline, were documented in 8 of 16 women who completed three cycles of the multidose regimen. Conclusion: CT scans are not a valid measure of response to i.p. SCH 58500 due to extensive adenoviral -induced inflammatory changes. Intraperitoneal SCH 58500 is safe, well tolerated, and combined with platinum -based chemotherapy can be associated with a significant reduction of serum CA125 in heavily pretreated patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

show abstract

“…Так, в работе J. Geisler и H. Geisler [10] медиана вы-живаемости составила 18,5 мес у пациенток с солитарным метастазом и 2,5 мес при множественном поражении. Медиана выживаемости была наиболее высокой при при-менении комплексного лечения.…”

Section: таблица 1 определение Rpa-класса (по Rtog 1997)unclassified

“…-уже у 1,3% больных [9]. По данным ряда авторов [9][10][11][12][13][14][15][16][17][18][19][20][21][22], среди метастазов в головном мозге метастазы РЯ составляют от 0,2 до 11,6%. Причиной низкой встречаемости, вероятно, является от-носительно низкая способность серозного РЯ к гемато-генному метастазированию.…”

unclassified

Treatment in patients with ovarian cancer metastasizing to the brain

Зайцев¹,

Новикова²,

Kirsanova³

et al. 2015

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Ключевые слова: метастазы в головном мозге, внутричерепные новообразования, рак яичников.The review gives the data available in the literature on the problem in treating patients with intracranial metastases from ovarian cancer (OC). The incidence of secondary brain involvement in OC has increased 6.5-fold in the last 20 years. The optimal treatment policy for intracerebral metastases from OC remains a complicated problem. If the foci are more than 3 cm, surgical treatment followed by chemotherapy and radiotherapy is recommended. If the foci are smaller, brain stereotactic radiosurgery followed by chemotherapy is the method of choice. The authors' investigation was conducted in 8 patients with brain metastases from OC, who had undergone microsurgical removal of a metastatic brain tumor, followed by multimodality treatment. After multimodality treatment, median overall survival was 15.0 months and median relapse-free survival was 11.5 months. Metastatic brain involvement is traditionally considered as a final manifestation of the disease and characterized by an extremely pessimistic prognosis. Our experience demonstrates that combination treatment involving surgery results in prolonged survival in patients who have a satisfactory quality of life. Keywords: breast cancer, intracranial neoplasms, ovarian cancer. © Коллектив авторов, 2015Кирсанова Ольга

show abstract

Brain Metastases in Epithelial Ovarian Carcinoma

Cited by 90 publications

References 0 publications

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

Brain Metastases from Epithelial Ovarian Cancer: A Review of the Literature

A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer

Treatment in patients with ovarian cancer metastasizing to the brain

Contact Info

Product

Resources

About